Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors

Keyphrases

• Tyrosine Kinase Inhibitor 100%
• Growth Factor Receptor Tyrosine Kinase 100%
• Peritoneal Mesothelioma 100%
• Kinase mutation 100%
• Somatic mutation 66%
• Tyrosine Kinase Domain 66%
• Epidermal Growth Factor Receptor 50%
• Genotype 50%
• TRK Inhibitors 50%
• Epidermal Growth Factor Receptor Gene 50%
• IC50 33%
• Tumor Specimens 33%
• Tumor Samples 33%
• Mesothelioma Cells 33%
• Polymorphism 16%
• Novel mutation 16%
• Direct Sequencing 16%
• Codon 16%
• Sequence Analysis 16%
• Clinical Response 16%
• Cancer Therapy 16%
• Promising Target 16%
• Established Cell Lines 16%
• Exon 21 16%
• Exon 20 16%
• Erlotinib 16%
• Sensitizing mutations 16%
• Lung Adenocarcinoma 16%
• Cell Tumor 16%
• Five Cells 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Peritoneal Mesothelioma 100%
• Neoplasm 44%
• IC50 22%
• Protein Tyrosine Kinase 22%
• Malignant Neoplasm 11%
• Erlotinib 11%
• Lung Adenocarcinoma 11%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Tyrosine Kinase Inhibitor 100%
• Somatic Mutation 44%
• Receptor Gene 33%
• Exon 22%
• Genotyping 22%
• Receptor Tyrosine Kinase 22%
• Tyrosine Kinase 22%
• IC50 22%
• Codon 11%
• Protein Sequencing 11%
• Erlotinib 11%